NASDAQ
1.91USD
-0.07 (-3.54%)
We have scored 6 news catalysts on TuHURA Biosciences, Inc. (HURA) over the past 12 months. The biggest single-day move next to one of them came Oct 5, 2026, when HURA closed −3.5%: “TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology”. Coverage across the window leans positive (average ticker sentiment +0.70). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
121.6M
P/E
—
EPS
—
Beta
-0.01
52W range
0.41-3.43
Day range
1.90–2.05
Open
2.00
Prev close
1.98
Volume
287.8K
Avg volume
396.9K
Dividend
0.00
IPO
2013-02-22
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about TuHURA Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for HURA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
